Please assess the completion status of the following clinical trial:

Trial Title: Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>= 18 years old~* Patients with colon or rectal carcinoma histologically proven~* Patients with metastases (synchronous or metachronous)~* Patients with associated extra-hepatic disease (asymptomatic primary tumor or extra-hepatic metastases)~* Performance status (World Health Organization \[WHO\]) = 0, 1, or 2~* Life expectancy \>= 3 months~* Patients with normal haematological, kidney, and liver parameters (PNN \> 1.5 x 10\^9/L, platelets \> 100 10\^9/L, total bilirubin \<= 1.25 x upper limit of normal (ULN), ASAT/ALAT \<= 5 x ULN, creatinaemia \<= 135 µmol/L (1.5 mg/dL)~* No cardiac or coronary insufficiency untreated~* At least 4 weeks between surgery and study beginning~* Patients can have a biopsy of the hepatic lesion identified by ultrasound.~* Informed consent signed.~Exclusion Criteria:~* Patients with symptomatic tumors (colon or rectal)~* Patients with others tumors not cured~* Patients who cannot be treated by 5-fluorouracil (5-FU) and/or irinotecan because of special medical conditions or other serious disease.~* Patients who participated in another clinical trial since less than 30 days~* Pregnancy or breast-feeding women~* Patients who cannot be treated because of active infection or other serious disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Bevacizumab
- 2 (Type: EXPERIMENTAL): Cetuximab

Based on this trial design, predict the completion outcome and termination type (if applicable).